Influence of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of sulfonylurea drugs

Current Drug Metabolism

Volumn 10, Issue 6, 2009, Pages 643-658

  Xu, Hongmei ^a   Murray, Michael ^a   McLachlan, Andrew John ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

Author keywords

CYP2C19; CYP2C9; Diabetes; KCNJ11; Pharmacodynamics; Pharmacokinetics; Polymorphism; Sulfonylurea; SUR1

Indexed keywords

ALANINE; ARGININE; CALPAIN 10; CHLORPROPAMIDE; CYSTEINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLYCINE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; INSULIN RECEPTOR SUBSTRATE 1; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; METFORMIN; SULFONYLUREA; SULFONYLUREA RECEPTOR; SULFONYLUREA RECEPTOR 1; THREONINE; TOLBUTAMIDE; TRANSCRIPTION FACTOR 7 LIKE 2;

ALLELE; AREA UNDER THE CURVE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; DRUG RELEASE; DRUG RESPONSE; ENZYME ACTIVITY; ETHNIC DIFFERENCE; EXON; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; POPULATION GENETICS; REVIEW; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TABLET;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYPOGLYCEMIC AGENTS; POLYMORPHISM, GENETIC; SULFONYLUREA COMPOUNDS;

EID: 70450133969     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009789375388     Document Type: Review

References (166)

1. Scobie, I.N. Atlas of Diabetes Mellitus. 3rd ed.; London: Informa Healthcare, 2006
2. Gale, E.A. Glucose control in the UKPDS: what did we learn? Diabetes Med., 2008, 25 (Suppl 2), 9-12. (Pubitemid 352020099)
3. Gloyn, A.L.; McCarthy, M.I. Genetics: how the UKPDS contributed to determining the genetic landscape of Type 2 diabetes. Diabet Med., 2008, 25 (Suppl 2), 35-40.
4. Bolen, S.; Feldman, L.; Vassy, J.; Wilson, L.; Yeh, H.C.; Marinopoulos, S.; Wiley, C.; Selvin, E.; Wilson, R.; Bass, E.B.; Brancati, F.L. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann. Intern. Med., 2007, 147(6), 386-399.
5. Mizuno, C.S.; Chittiboyina, A.G.; Kurtz, T.W.; Pershadsingh, H.A.; Avery, M.A. Type 2 diabetes and oral antihyperglycemic drugs. Curr. Med. Chem., 2008, 15(1), 61-74. (Pubitemid 351234628)
6. Bozkurt, O.; de Boer, A.; Grobbee, D.E.; Heerdink, E.R.; Burger, H.; Klungel, O.H. Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Mol. Diagn. Ther., 2007, 11(5), 291-302. (Pubitemid 350014793)
7. Elliot, D.J.; Suharjono.; Lewis, B.C.; Gillam, E.M.; Birkett, D.J.; Gross, A.S.; Miners, J.O. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. Br. J. Clin. Pharmacol., 2007, 64(4), 450-457.
8. Rosemary, J.; Adithan, C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr. Clin. Pharmacol., 2007, 2(1), 93-109. (Pubitemid 46729082)
9. Aguilar-Bryan, L.; Bryan, J. Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocr. Rev., 1999, 20(2), 101-135. (Pubitemid 29339588)
10. Ashcroft, F.M. K(ATP) channels and insulin secretion: a key role in health and disease. Biochem. Soc. Trans., 2006, 34(Pt 2), 243-246.
11. Proks, P.; Reimann, F.; Green, N.; Gribble, F.; Ashcroft, F. Sulfonylurea stimulation of insulin secretion. Diabetes, 2002, 51 (Suppl 3), S368-376.
12. Feng, Y.; Mao, G.; Ren, X.; Xing, H.; Tang, G.; Li, Q.; Li, X.; Sun, L.; Yang, J.; Ma, W.; Wang, X.; Xu, X. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care, 2008, 31(10), 1939-1944.
13. Rafiq, M.; Flanagan, S.E.; Patch, A.M.; Shields, B.M.; Ellard, S. and Hattersley, A.T. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care, 2008, 31(2), 204-209. (Pubitemid 351213320)
14. Kirchheiner, J.; Roots, I.; Goldammer, M.; Rosenkranz, B.; Brockmoller, J. Effect of genetic polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet., 2005, 44(12), 1209-1225. (Pubitemid 41832564)
15. Wilkinson, G.R. Drug metabolism and variability among patients in drug response. N. Engl. J. Med., 2005, 352(21), 2211-2221.
16. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 1994, 270(1), 414-423.
17. Inoue, K.; Yamazaki, H.; Imiya, K.; Akasaka, S.; Guengerich, F.P.; Shimada, T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 1997, 7(2), 103-113. (Pubitemid 27261842)
18. Wijnen, P.A.; Op den Buijsch, R.A.; Drent, M.; Kuipers, P.M.; Neef, C.; Bast, A.; Bekers, O.; Koek, G.H. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment. Pharmacol. Ther., 2007, 26 (Suppl 2), 211-219.
19. Takahashi, H.; Kashima, T.; Nomoto, S. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin:catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics, 1998, 8, 365-373. (Pubitemid 28475300)
20. Soga, Y.; Nishimura, F.; Ohtsuka, Y.; Araki, H.; Iwamoto, Y.; Naruishi, H. and al., e. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Life Sci., 2004, 74(7), 827-834. (Pubitemid 37501131)
21. Yasar, U.; Forslund-Bergengren, C.; Tybring, G.; Dorado, P.; Llerena, A.; Sjoqvist, F.; Eliasson, E.; Dahl, M.L. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther., 2002, 71(1), 89-98. (Pubitemid 34124042)
22. Kirchheiner, J.; Bauer, S.; Meineke, I.; Rohde, W.; Prang, V.; Meisel, C.; Roots, I.; Brockmoller, J. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics, 2002, 12(2), 101-109. (Pubitemid 34298914)
23. Martinez, C.; Blanco, G.; Ladero, J.M.; Garcia-Martin, E.; Taxonera, C.; Gamito, F.G.; Diaz-Rubio, M.; Agundez, J.A. Genetic pre-disposition to acute gastrointestinal bleeding after NSAIDs use. Br. J. Pharmacol., 2004, 141(2), 205-208. (Pubitemid 38250889)
24. Aithal, G.P.; Day, C.P.; Leathart, J.B.; Daly, A.K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics, 2000, 511-518.
25. Tang, C.; Shou, M.; Mei, Q.; Rushmore, T.H.; Rodrigues, A.D. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase- II inhibitor. J. Pharmacol. Exp. Ther, 2000, 293(2), 453-459.
26. Solus, J.F.; Arietta, B.J.; Harris, J.R.; Sexton, D.P.; Steward, J.Q.; McMunn, C.; Ihrie, P.; Mehall, J.M.; Edwards, T.L.; Dawson, E.P. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics, 2004, 5(7), 895-931.
27. Xie, H.G.; Prasad, H.C.; Kim, R.B.; Stein, C.M. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev., 2002, 54(10), 1257-1270.
28. Kirchheiner, J.; Brockmoller, J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther., 2005, 77(1), 1-16. (Pubitemid 40089477)
29. Sullivan-Klose, T.H.; Ghanayem, B.I.; Bell, D.A.; Zhang, Z.Y.; Kaminsky, L.S.; Shenfield, G.M.; Miners, J.O.; Birkett, D.J.; Goldstein, J.A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 1996, 6(4), 341-349.
30. Maekawa, K.; Fukushima-Uesaka, H.; Tohkin, M.; Hasegawa, R.; Kajio, H.; Kuzuya, N.; Yasuda, K.; Kawamoto, M.; Kamatani, N.; Suzuki, K.; Yanagawa, T.; Saito, Y.; Sawada, J. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet. Genomics, 2006, 16(7), 497-514. (Pubitemid 43922347)
31. DeLozier, T.C.; Lee, S.C.; Coulter, S.J.; Goh, B.C.; Goldstein, J.A. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J. Pharmacol. Exp. Ther., 2005, 315(3), 1085-1090.
32. Blaisdell, J.; Jorge-Nebert, L.F.; Coulter, S.; Ferguson, S.S.; Lee, S.J.; Chanas, B.; Xi, T.; Mohrenweiser, H.; Ghanayem, B.; Goldstein, J.A. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics, 2004, 14(8), 527-537.
33. Veenstra, D.L.; Blough, D.K.; Higashi, M.K.; Farin, F.M.; Srinouanprachan, S.; Rieder, M.J.; Rettie, A.E. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther., 2005, 77(5), 353-364.
34. Goldstein, J.A. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol., 2001, 52(4), 349-355.
35. Aithal, G.P.; Day, C.P.; Kesteven, P.J.; Daly, A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353(9154), 717-719.
36. van der Weide, J.; Steijns, L.S.; van Weelden, M.J.; de Haan, K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics, 2001, 11(4), 287-291. (Pubitemid 32537401)
37. Rettie, A.E.; Haining, R.L.; Bajpai, M.; Levy, R.H. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res., 1999, 35(3), 253-255.
38. Takanashi, K.; Tainaka, H.; Kobayashi, K.; Yasumori, T.; Hosakawa, M.; Chiba, K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics, 2000, 10(2), 95-104.
39. Lee, S.S.; Kim, K.M.; Thi-Le, H.; Yea, S.S.; Cha, I.J.; Shin, J.G. Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population. Ther. Drug Monit., 2005, 27(2), 208-210. (Pubitemid 40463651)
40. Nasu, K.; Kubota, T.; Ishizaki, T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics, 1997, 7(5), 405-409. (Pubitemid 27427552)
41. Wang, S.L.; Huang, J.; Lai, M.D.; Tsai, J.J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics, 1995, 5(1), 37-42.
42. Yoon, Y.R.; Shon, J.H.; Kim, M.K.; Lim, Y.C.; Lee, H.R.; Park, J.Y.; Cha, I.J.; Shin, J.G. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br. J. Clin. Pharmacol., 2001, 51(3), 277-280.
43. Garcia-Martin, E.; Martinez, C.; Ladero, J.M.; Gamito, F.J.; and Agundez, J.A. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population. Eur. J. Clin. Pharmacol., 2001, 57(1), 47-49.
44. Garcia-Martin, E.; Martinez, C.; Tabares, B.; Frias, J.; Agundez, J.A. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther., 2004, 76(2), 119-127.
45. Mas, S.; Crescenti, A.; Vidal-Taboada, J.M.; Bergonon, S.; Cuevillas, F.; Laso, N.; Molina, R.; Ballesta, A.; Lafuente, A. Simultaneous genotyping of CYP2C9*2, *3, and 5′ flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis. Eur. J. Clin. Pharmacol., 2005, 61(9), 635-641.
46. Dickmann, L.J.; Rettie, A.E.; Kneller, M.B.; Kim, R.B.; Wood, A.J.J.; Stein, C.M.; Wilkinson, G.R.; Schwarz, U.I. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol., 2001, 60, 382-387.
47. Yasar, U.; Aklillu, E.; Canaparo, R.; Sandberg, M.; Sayi, J.; Roh, H.K.; Wennerholm, A. Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur. J. Clin. Pharmacol., 2002, 58(8), 555-558. (Pubitemid 35435508)
48. Allabi, A.C.; Gala, J.L.; Horsmans, Y.; Babaoglu, M.O.; Bozkurt, A.; Heusterspreute, M.; Yasar, U. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in. vivo among black Africans. Clin. Pharmacol. Ther, 2004, 76(2), 113-118. (Pubitemid 39013401)
49. Scordo, M.G.; Caputi, A.P.; D'Arrigo, C.; Fava, G.; Spina, E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol. Res., 2004, 50(2), 195-200.
50. Takahashi, H.; Wilkinson, G.R.; Caraco, Y.; Muszkat, M.; Kim, R.B.; Kashima, T.; Kimura, S.; Echizen, H. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther., 2003, 73(3), 253-263. (Pubitemid 36269676)
51. Kirchheiner, J.; Brockmoller, J.; Meineke, I.; Bauer, S.; Rohde, W.; Meisel, C.; Roots, I. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther., 2002, 71(4), 286-296. (Pubitemid 34311458)
52. Niemi, M.; Cascorbi, I.; Timm, R.; Kroemer, H.K.; Neuvonen, P.J.; Kivisto, K.T. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin. Pharmacol. Ther., 2002, 72(3), 326-332.
53. Ravindran, S.; Zharikova, O.L.; Hill, R.A.; Nanovskaya, T.N.; Hankins, G.D.; Ahmed, M.S. Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons. Biochem. Pharmacol., 2006, 72(12), 1730-1737.
54. Yin, O.Q.; Tomlinson, B.; Chow, M.S. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin. Pharmacol. Ther., 2005, 78(4), 370-377.
55. Zhang, Y.F.; Chen, X.Y.; Guo, Y.J.; Si, D.Y.; Zhou, H.; Zhong, D.F. [Impact of cytochrome P450 CYP2C9 variant allele CYP2C9*3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects]. Yao. Xue. Xue. Bao, 2005, 40(9), 796-799.
56. Kidd, R.S.; Straughn, A.B.; Meyer, M.C.; Blaisdell, J.; Goldstein, J.A.; Dalton, J.T. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics, 1999, 9(1), 71-80.
57. Scott, J.; Poffenbarger, P.L. Pharmacogenetics of tolbutamide metabolism in humans. Diabetes, 1979, 28(1), 41-51.
58. Miners, J. CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response. Pharmacogenetics, 2002, 12(2), 91-92. (Pubitemid 34298912)
59. Sansom, L.N. Australian Pharmaceutical Formulary and Handbook 21st ed.; Canberra: Pharmaceutical Society of Australia, 2009.
60. Shon, J.H.; Yoon, Y.R.; Kim, K.A.; Lim, Y.C.; Lee, K.J.; Park, J.Y.; Cha, I.J.; Flockhart, D.A.; Shin, J.G. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics, 2002, 12(2), 111-119.
61. Lee, C.R.; Pieper, J.A.; Hinderliter, A.L.; Blaisdell, J.A.; Goldstein, J.A. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C9*1 heterozygotes. Clin. Pharmacol. Ther., 2002, 72(5), 562-571.
62. Jetter, A.; Kinzig-Schippers, M.; Skott, A.; Lazar, A.; Tomalik- Scharte, D.; Kirchheiner, J.; Walchner-Bonjean, M.; Hering, U.; Jakob, V.; Rodamer, M.; Jabrane, W.; Kasel, D.; Brockmoller, J.; Fuhr, U.; Sorgel, F. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur. J. Clin. Pharmacol., 2004, 60(3), 165-171. (Pubitemid 38757127)
63. Chen, K.; Wang, R.; Wen, S.Y.; Li, J.; Wang, S.Q. Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide. J. Clin. Pharm. Ther., 2005, 30(3), 241-249. (Pubitemid 41603047)
64. Li, J.; Wen, S.Y.; Wang, R.; Chen, K.; Fang, Y.; Pei, F.; Wang, S.Q. [Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray]. Yao. Xue. Xue. Bao, 2005, 40(8), 695-699.
65. Becker, M.L.; Visser, L.E.; Trienekens, P.H.; Hofman, A.; van Schaik, R.H.; Stricker, B.H. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin. Pharmacol. Ther., 2008, 83(2), 288-292.
66. 2005. Australian Statistics on Medicines 2003. ed.: Dept of Health & Ageing, Commonwealth of Australia, 2003.
67. Wang, R.; Chen, K.; Wen, S.Y.; Li, J.; Wang, S.Q. Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clin. Pharmacol. Ther., 2005, 78(1), 90-92. (Pubitemid 40956936)
68. Zhang, Y.; Si, D.; Chen, X.; Lin, N.; Guo, Y.; Zhou, H.; Zhong, D. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br. J. Clin. Pharmacol., 2007, 64(1), 67-74. (Pubitemid 46934414)
69. Xu, H.; Williams, K.M.; Liauw, W.S.; Murray, M.; Day, R.O.; McLachlan, A.J. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br. J. Pharmacol., 2008, 153(7), 1579-1586.
70. Yoon, Y.R.; Shon, J.H.; Kim, K.A.; Cha, I.J.; Shin, S.G.; Shin, J.G. Pharmacokinetics and pharmacodynamics of tolbutamide and chlorpropamide in relation to CYP2C9 and CYP2C19 [poster]. Clin. Pharmacol. Ther., 2000, 67, 152.
71. Shon, J.H.; Yoon, Y.R.; Kim, M.J.; Kim, K.A.; Lim, Y.C.; Liu, K.H.; Shin, D.H.; Lee, C.H.; Cha, I.J.; Shin, J.G. Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in. vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br. J. Clin. Pharmacol., 2005, 59(5), 552-563.
72. Campbell, R.K.; Hansten, P.D. Metabolism of chlorpropamide. Diabetes Care, 1981, 4(2), 332.
73. Holstein, A.; Plaschke, A.; Ptak, M.; Egberts, E.; El-Din, J.; Brockmoller, J.; Kirchheiner, J. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol., 2005, 60(1), 103-106. (Pubitemid 40942788)
74. Evans, W.E.; Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 1999, 286(5439), 487-491.
75. Lasker, J.M.; Wester, M.R.; Aramsombatdee, E.; Raucy, J.L. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch. Biochem. Biophys., 1998, 353(1), 16-28.
76. Inomata, S.; Nagashima, A.; Itagaki, F.; Homma, M.; Nishimura, M.; Osaka, Y.; Okuyama, K.; Tanaka, E.; Nakamura, T.; Kohda, Y.; Naito, S.; Miyabe, M.; Toyooka, H. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin. Pharmacol. Ther, 2005, 78(6), 647-655. (Pubitemid 41773640)
77. Kobayashi, K.; Morita, J.; Chiba, K.; Wanibuchi, A.; Kimura, M.; Irie, S.; Urae, A.; Ishizaki, T. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans. Pharmacogenetics, 2004, 14(8), 549-556. (Pubitemid 39100006)
78. Mamiya, K.; Hadama, A.; Yukawa, E.; Ieiri, I.; Otsubo, K.; Ninomiya, H.; Tashiro, N.; Higuchi, S. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur. J. Clin. Pharmacol., 2000, 55(11-12), 821-825. (Pubitemid 30201764)
79. Yokono, A.; Morita, S.; Someya, T.; Hirokane, G.; Okawa, M.; Shimoda, K. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. J. Clin. Psychopharmacol., 2001, 21(6), 549-555. (Pubitemid 33116652)
80. Xie, H.G.; Kim, R.B.; Wood, A.J.; Stein, C.M. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 815-850. (Pubitemid 32385908)
81. Rogers, J.F.; Nafziger, A.N.; Bertino, J.S., Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am. J. Med., 2002, 113(9), 746-750.
82. Mizutani, T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev., 2003, 35(2-3), 99-106. (Pubitemid 37048293)
83. Rydberg, T.; Jonsson, A.; Roder, M.; Melander, A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care, 1994, 17(9), 1026-1030. (Pubitemid 24268615)
84. Ferner, R.E.; Chaplin, S. The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin. Pharmacokinet., 1987, 12(6), 379-401.
85. Laukkanen, O.; Pihlajamaki, J.; Lindstrom, J.; Eriksson, J.; Valle, T.T.; Hamalainen, H.; Ilanne-Parikka, P.; Keinanen-Kiukaanniemi, S.; Tuomilehto, J.; Uusitupa, M.; Laakso, M. Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study. J. Clin. Endocrinol. Metab., 2004, 89(12), 6286-6290. (Pubitemid 39628447)
86. Yokoi, N.; Kanamori, M.; Horikawa, Y.; Takeda, J.; Sanke, T.; Furuta, H.; Nanjo, K.; Mori, H.; Kasuga, M.; Hara, K.; Kadowaki, T.; Tanizawa, Y.; Oka, Y.; Iwami, Y.; Ohgawara, H.; Yamada, Y.; Seino, Y.; Yano, H.; Cox, N.J.; Seino, S. Association studies of variants in the genes involved in pancreatic beta-cell function in type 2 diabetes in Japanese subjects. Diabetes, 2006, 55(8), 2379-2386. (Pubitemid 44743638)
87. Reis, A.F.; Velho, G. Sulfonylurea receptor -1 (SUR1): genetic and metabolic evidences for a role in the susceptibility to type 2 diabetes mellitus. Diabetes Metab., 2002, 28(1), 14-19. (Pubitemid 34168745)
88. Weisnagel, S.J.; Rankinen, T.; Nadeau, A.; Rao, D.C.; Chagnon, Y.C.; Perusse, L.; Bouchard, C. Decreased fasting and oral glucose stimulated C-peptide in nondiabetic subjects with sequence variants in the sulfonylurea receptor 1 gene. Diabetes, 2001, 50(3), 697-702. (Pubitemid 32195239)
89. Zhang, H.; Liu, X.; Kuang, H.; Yi, R.; Xing, H. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res. Clin. Pract., 2007, 77(1), 58-61. (Pubitemid 46590477)
90. Reis, A.F.; Ye, W.Z.; Dubois-Laforgue, D.; Bellanne-Chantelot, C.; Timsit, J.; Velho, G. Association of a variant in exon 31 of the sulfonylurea receptor 1 (SUR1) gene with type 2 diabetes mellitus in French Caucasians. Hum. Genet., 2000, 107(2), 138-144. (Pubitemid 30686966)
91. van Dam, R.M.; Hoebee, B.; Seidell, J.C.; Schaap, M.M.; de Bruin, T.W.; Feskens, E.J. Common variants in the ATP-sensitive K+ channel genes KCNJ11 (Kir6.2) and ABCC8 (SUR1) in relation to glucose intolerance: population-based studies and meta-analyses. Diabet. Med., 2005, 22(5), 590-598.
92. Hart, L.M.; Dekker, J.M.; van Haeften, T.W.; Ruige, J.B.; Stehouwer, C.D.; Erkelens, D.W.; Heine, R.J.; Maassen, J.A. Reduced second phase insulin secretion in carriers of a sulphonylurea receptor gene variant associating with Type II diabetes mellitus. Diabetologia, 2000, 43(4), 515-519.
93. Rissanen, J.; Markkanen, A.; Karkkainen, P.; Pihlajamaki, J.; Kekalainen, P.; Mykkanen, L.; Kuusisto, J.; Karhapaa, P.; Niskanen, L.; Laakso, M. Sulfonylurea receptor 1 gene variants are associated with gestational diabetes and type 2 diabetes but not with altered secretion of insulin. Diabetes Care, 2000, 23(1), 70-73. (Pubitemid 30022897)
94. Stefanski, A.; Majkowska, L.; Ciechanowicz, A.; Frankow, M.; Safranow, K.; Parczewski, M.; Pilarska, K. The common C49620T polymorphism in the sulfonylurea receptor gene (ABCC8), pancreatic beta cell function and long-term diabetic complications in obese patients with long-lasting type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes, 2007, 115(5), 317-321. (Pubitemid 46877865)
95. Hansen, T.; Echwald, S.M.; Hansen, L.; Moller, A.M.; Almind, K.; Clausen, J.O.; Urhammer, S.A.; Inoue, H.; Ferrer, J.; Bryan, J.; Aguilar-Bryan, L.; Permutt, M.A.; Pedersen, O. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes, 1998, 47(4), 598-605. (Pubitemid 28160451)
96. Wang, Z.; Gorski, J.C.; Hamman, M.A.; Huang, S.M.; Lesko, L.J.; Hall, S.D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther., 2001, 70(4), 317-326. (Pubitemid 33022472)
97. Goksel, D.L.; Fischbach, K.; Duggirala, R.; Mitchell, B.D.; Aguilar- Bryan, L.; Blangero, J.; Stern, M.P.; O'Connell, P. Variant in sulfonylurea receptor-1 gene is associated with high insulin concentrations in non-diabetic Mexican Americans: SUR-1 gene variant and hyperinsulinemia. Hum. Genet., 1998, 103(3), 280-285. (Pubitemid 28470077)
98. Sakura, H.; Wat, N.; Horton, V.; Millns, H.; Turner, R.C.; Ashcroft, F.M. Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro. Diabetologia, 1996, 39(10), 1233-1236.
99. Inoue, H.; Ferrer, J.; Warren-Perry, M.; Zhang, Y.; Millns, H.; Turner, R.C.; Elbein, S.C.; Hampe, C.L.; Suarez, B.K.; Inagaki, N.; Seino, S.; Permutt, M.A. Sequence variants in the pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. Diabetes, 1997, 46(3), 502-507.
100. Hansen, L.; Echwald, S.M.; Hansen, T.; Urhammer, S.A.; Clausen, J.O.; Pedersen, O. Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes, 1997, 46(3), 508-512. (Pubitemid 27090283)
101. Altshuler, D.; Hirschhorn, J.N.; Klannemark, M.; Lindgren, C.M.; Vohl, M.C.; Nemesh, J.; Lane, C.R.; Schaffner, S.F.; Bolk, S.; Brewer, C.; Tuomi, T.; Gaudet, D.; Hudson, T.J.; Daly, M.; Groop, L.; Lander, E.S. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet., 2000, 26(1), 76-80.
102. Hani, E.H.; Boutin, P.; Durand, E.; Inoue, H.; Permutt, M.A.; Velho, G.; Froguel, P. Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of Type II diabetes mellitus in Caucasians. Diabetologia, 1998, 41(12), 1511-1515. (Pubitemid 28551623)
103. Gloyn, A.L.; Hashim, Y.; Ashcroft, S.J.; Ashfield, R.; Wiltshire, S.; Turner, R.C. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet. Med., 2001, 18(3), 206-212.
104. Gloyn, A.L.; Weedon, M.N.; Owen, K.R.; Turner, M.J.; Knight, B.A.; Hitman, G.; Walker, M.; Levy, J.C.; Sampson, M.; Halford, S.; McCarthy, M.I.; Hattersley, A.T.; Frayling, T.M. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes, 2003, 52(2), 568-572.
105. Barroso, I.; Luan, J.; Middelberg, R.P.; Harding, A.H.; Franks, P.W.; Jakes, R.W.; Clayton, D.; Schafer, A.J.; O'Rahilly, S.; Wareham, N.J. Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. PLoS Biol., 2003, 1(1), E20.
106. Nielsen, E.M.; Hansen, L.; Carstensen, B.; Echwald, S.M.; Drivsholm, T.; Glumer, C.; Thorsteinsson, B.; Borch-Johnsen, K.; Hansen, T.; Pedersen, O. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. Diabetes, 2003, 52(2), 573-577. (Pubitemid 36173219)
107. Love-Gregory, L.; Wasson, J.; Lin, J.; Skolnick, G.; Suarez, B.; Permutt, M.A. E23K single nucleotide polymorphism in the islet ATP-sensitive potassium channel gene (Kir6.2) contributes as much to the risk of Type II diabetes in Caucasians as the PPAR-gamma Pro12Ala variant. Diabetologia, 2003, 46(1), 136-137.
108. Florez, J.C.; Burtt, N.; de Bakker, P.I.; Almgren, P.; Tuomi, T.; Holmkvist, J.; Gaudet, D.; Hudson, T.J.; Schaffner, S.F.; Daly, M.J.; Hirschhorn, J.N.; Groop, L.; Altshuler, D. Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes, 2004, 53(5), 1360-1368. (Pubitemid 38569024)
109. Sakamoto, Y.; Inoue, H.; Keshavarz, P.; Miyawaki, K.; Yamaguchi, Y.; Moritani, M.; Kunika, K.; Nakamura, N.; Yoshikawa, T.; Yasui, N.; Shiota, H.; Tanahashi, T.; Itakura, M. SNPs in the KCNJ11-ABCC8 gene locus are associated with type 2 diabetes and blood pressure levels in the Japanese population. J. Hum. Genet., 2007, 52(10), 781-793. (Pubitemid 47512860)
110. Cauchi, S.; Froguel, P. TCF7L2 genetic defect and type 2 diabetes. Curr. Diabet. Rep., 2008, 8(2), 149-155.
111. Kimber, C.H.; Doney, A.S.; Pearson, E.R.; McCarthy, M.I.; Hattersley, A.T.; Leese, G.P.; Morris, A.D.; Palmer, C.N. TCF7L2 in the Go-DARTS study: evidence for a gene dose effect on both diabetes susceptibility and control of glucose levels. Diabetologia, 2007, 50(6), 1186-1191.
112. Florez, J.C.; Jablonski, K.A.; Bayley, N.; Pollin, T.I.; de Bakker, P.I.; Shuldiner, A.R.; Knowler, W.C.; Nathan, D.M.; Altshuler, D. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med., 2006, 355(3), 241-250. (Pubitemid 44079339)
113. Florez, J.C. The new type 2 diabetes gene TCF7L2. Curr. Opin. Clin. Nutr. Metab. Care, 2007, 10(4), 391-396. (Pubitemid 46934105)
114. Pearson, E.R.; Donnelly, L.A.; Kimber, C.; Whitley, A.; Doney, A.S.; McCarthy, M.I.; Hattersley, A.T.; Morris, A.D.; Palmer, C.N. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes, 2007, 56(8), 2178-2182.
115. Winter, W.E.; Nakamura, M.; House, D.V. Monogenic diabetes mellitus in youth. The MODY syndromes. Endocrinol. Metab. Clin. North. Am., 1999, 28(4), 765-785.
116. Sagen, J.V.; Pearson, E.R.; Johansen, A.; Spyer, G.; Sovik, O.; Pedersen, O.; Njolstad, P.R.; Hattersley, A.T.; Hansen, T. Preserved insulin response to tolbutamide in hepatocyte nuclear factor-1alpha mutation carriers. Diabet. Med., 2005, 22(4), 406-409. (Pubitemid 40516238)
117. Sovik, O.; Njolstad, P.; Folling, I.; Sagen, J.; Cockburn, B.N.; Bell, G.I. Hyperexcitability to sulphonylurea in MODY3. Diabetologia, 1998, 41(5), 607-608.
118. Hathout, E.H.; Cockburn, B.N.; Mace, J.W.; Sharkey, J.; Chen-Daniel, J.; Bell, G.I. A case of hepatocyte nuclear factor-1 alpha diabetes/MODY3 masquerading as type 1 diabetes in a Mexican-American adolescent and responsive to a low dose of sulfonylurea. Diabet. Care, 1999, 22(5), 867-868.
119. Pearson, E.R.; Liddell, W.G.; Shepherd, M.; Corrall, R.J.; and Hattersley, A.T. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet. Med., 2000, 17(7), 543-545.
120. Pearson, E.R.; Starkey, B.J.; Powell, R.J.; Gribble, F.M.; Clark, P.M.; Hattersley, A.T. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet, 2003, 362(9392), 1275-1281. (Pubitemid 37324255)
121. Keller, S.R.; Lienhard, G.E. Insulin signalling: the role of insulin receptor substrate 1. Trends Cell. Biol., 1994, 4(4), 115-119. (Pubitemid 24107705)
122. Sesti, G.; Marini, M.A.; Cardellini, M.; Sciacqua, A.; Frontoni, S.; Andreozzi, F.; Irace, C.; Lauro, D.; Gnasso, A.; Federici, M.; Perticone, F.; Lauro, R. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabet. Care, 2004, 27(6), 1394-1398. (Pubitemid 38679989)
123. Ertunc, D.; Tok, E.C.; Aktas, A.; Erdal, E.M.; Dilek, S. The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. Hum. Reprod., 2005, 20(5), 1207-1212. (Pubitemid 40790243)
124. Hanis, C.L.; Boerwinkle, E.; Chakraborty, R.; Ellsworth, D.L.; Concannon, P.; Stirling, B.; Morrison, V.A.; Wapelhorst, B.; Spielman, R.S.; Gogolin-Ewens, K.J.; Shepard, J.M.; Williams, S.R.; Risch, N.; Hinds, D.; Iwasaki, N.; Ogata, M.; Omori, Y.; Petzold, C.; Rietzch, H.; Schroder, H.E.; Schulze, J.; Cox, N.J.; Menzel, S.; Boriraj, V.V.; Chen, X.; Lim, L.R.; Lindner, T.; Mereu, L.E.; Wang, Y.Q.; Xiang, K.; Yamagata, K.; Yang, Y.; Bell, G.I. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat. Genet., 1996, 13(2), 161-166.
125. Cox, N.J.; Hayes, M.G.; Roe, C.A.; Tsuchiya, T.; Bell, G.I. Linkage of calpain 10 to type 2 diabetes: the biological rationale. Diabetes, 2004, 53 (Suppl. 1), S19-25.
126. Song, Y.; Niu, T.; Manson, J.E.; Kwiatkowski, D.J.; Liu, S. Are variants in the CAPN10 gene related to risk of type 2 diabetes? A quantitative assessment of population and family-based association studies. Am. J. Hum. Genet., 2004, 74(2), 208-222. (Pubitemid 38168609)
127. Tsuchiya, T.; Schwarz, P.E.; Bosque-Plata, L.D.; Geoffrey Hayes, M.; Dina, C.; Froguel, P.; Wayne Towers, G.; Fischer, S.; Temelkova-Kurktschiev, T.; Rietzsch, H.; Graessler, J.; Vcelak, J.; Palyzova, D.; Selisko, T.; Bendlova, B.; Schulze, J.; Julius, U.; Hanefeld, M.; Weedon, M.N.; Evans, J.C.; Frayling, T.M.; Hattersley, A.T.; Orho-Melander, M.; Groop, L.; Malecki, M.T.; Hansen, T.; Pedersen, O.; Fingerlin, T.E.; Boehnke, M.; Hanis, C.L.; Cox, N.J.; and Bell, G.I. Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses. Mol. Genet. Metab., 2006, 89(1-2), 174-184.
128. Saez, M.E.; Gonzalez-Sanchez, J.L.; Ramirez-Lorca, R.; Martinez-Larrad, M.T.; Zabena, C.; Gonzalez, A.; Moron, F.J.; Ruiz, A.; Serrano-Rios, M. The CAPN10 gene is associated with insulin resistance phenotypes in the Spanish population. PLoS ONE, 2008, 3(8), e2953.
129. Scordo, M.G.; Aklillu, E.; Yasar, U.; Dahl, M.L.; Spina, E.; Ingelman- Sundberg, M. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol., 2001, 52(4), 447-450. (Pubitemid 32939447)
130. Margaglione, M.; Colaizzo, D.; D'Andrea, G.; Brancaccio, V.; Ciampa, A.; Grandone, E.; Di Minno, G. Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost., 2000, 84(5), 775-778. (Pubitemid 30946935)
131. Taube, J.; Halsall, D.; Baglin, T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood, 2000, 96(5), 1816-1819. (Pubitemid 30661066)
132. Yasar, U.; Eliasson, E.; Dahl, M.L.; Johansson, I.; Ingelman- Sundberg, M.; Sjoqvist, F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem. Biophys. Res. Commun., 1999, 254(3), 628-631. (Pubitemid 29290517)
133. Sandberg, M.; Johansson, I.; Christensen, M.; Rane, A.; Eliasson, E. The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. Drug Metab. Dispos., 2004, 32(5), 484-489. (Pubitemid 38535025)
134. Topic, E.; Stefanovic, M.; Samardzija, M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. Clin. Chem. Lab. Med., 2004, 42(1), 72-78. (Pubitemid 38401472)
135. Yang, J.Q.; Morin, S.; Verstuyft, C.; Fan, L.A.; Zhang, Y.; Xu, C.D.; Barbu, V.; Funck-Brentano, C.; Jaillon, P.; Becquemont, L. Frequency of cytochrome P450 2C9 allelic variants in the Chinese and French populations. Fundam. Clin. Pharmacol., 2003, 17(3), 373-376. (Pubitemid 36774173)
136. Bravo-Villalta, H.V.; Yamamoto, K.; Nakamura, K.; Baya, A.; Okada, Y.; Horiuchi, R. Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. Eur. J. Clin. Pharmacol., 2005, 61(3), 179-184. (Pubitemid 40768549)
137. Allabi, A.C.; Gala, J.L.; Desager, J.P.; Heusterspreute, M.; Horsmans, Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br. J. Clin. Pharmacol., 2003, 56(6), 653-657. (Pubitemid 37491717)
138. Aynacioglu, A.S.; Brockmoller, J.; Bauer, S.; Sachse, C.; Guzelbey, P.; Ongen, Z.; Nacak, M.; Roots, I. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharmacol., 1999, 48(3), 409-415. (Pubitemid 29417726)
139. Limdi, N.A.; McGwin, G.; Goldstein, J.A.; Beasley, T.M.; Arnett, D.K.; Adler, B.K.; Baird, M.F.; Acton, R.T. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin. Pharmacol. Ther, 2008, 83(2), 312-321.
140. Scott, S.A.; Edelmann, L.; Kornreich, R.; Erazo, M.; Desnick, R.J. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics, 2007, 8(7), 721-730.
141. Hamdy, S.I.; Hiratsuka, M.; Narahara, K.; El-Enany, M.; Moursi, N.; Ahmed, M.S.; Mizugaki, M. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin. Pharmacol., 2002, 53(6), 596-603.
142. Lee, C.R.; Goldstein, J.A.; Pieper, J.A. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 2002, 12(3), 251-263.
143. Gaikovitch, E.A.; Cascorbi, I.; Mrozikiewicz, P.M.; Brockmoller, J.; Frotschl, R.; Kopke, K.; Gerloff, T.; Chernov, J.N.; Roots, I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol., 2003, 59(4), 303-312. (Pubitemid 37100349)
144. Lamba, J.K.; Dhiman, R.K.; Kohli, K.K. CYP2C19 genetic mutations in North Indians. Clin. Pharmacol. Ther, 2000, 68(3), 328-335.
145. Jose, R.; Chandrasekaran, A.; Sam, S.S.; Gerard, N.; Chanolean, S.; Abraham, B.K.; Satyanarayanamoorthy, K.; Peter, A.; Rajagopal, K. CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population. Fundam. Clin. Pharmacol., 2005, 19(1), 101-105. (Pubitemid 40204352)
146. Halling, J.; Petersen, M.S.; Damkier, P.; Nielsen, F.; Grandjean, P.; Weihe, P.; Lundgren, S.; Lundblad, M.S.; Brosen, K. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur. J. Clin. Pharmacol., 2005, 61(7), 491-497. (Pubitemid 41222295)
147. Ragia, G.; Arvanitidis, K.I.; Tavridou, A.; Manolopoulos, V.G. Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. Pharmacogenomics, 2009, 10(1), 43-49.
148. Ruas, J.L.; Lechner, M.C. Allele frequency of CYP2C19 in a Portuguese population. Pharmacogenetics, 1997, 7(4), 333-335.
149. Yamada, H.; Dahl, M.L.; Lannfelt, L.; Viitanen, M.; Winblad, B.; Sjoqvist, F. CYP2D6 and CYP2C19 genotypes in an elderly Swedish population. Eur. J. Clin. Pharmacol., 1998, 54(6), 479-481. (Pubitemid 28418816)
150. Bathum, L.; Andersen-Ranberg, K.; Boldsen, J.; Brosen, K.; Jeune, B. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevitY. Role of CYP2D6 and CYP2C19 in longevity. Eur. J. Clin. Pharmacol., 1998, 54(5), 427-430. (Pubitemid 28396317)
151. Aynacioglu, A.S.; Sachse, C.; Bozkurt, A.; Kortunay, S.; Nacak, M.; Schroder, T.; Kayaalp, S.O.; Roots, I.; Brockmoller, J. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin. Pharmacol. Ther., 1999, 66(2), 185-192. (Pubitemid 29398854)
152. Sviri, S.; Shpizen, S.; Leitersdorf, E.; Levy, M.; Caraco, Y. Phenotypic- genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin. Pharmacol. Ther, 1999, 65(3), 275-282. (Pubitemid 29142933)
153. Sameer, A.E.; Amany, G.M.; Abdela, A.A.; Fadel, S.A. CYP2C19 genotypes in a population of healthy volunteers and in children with hematological malignancies in Gaza Strip. Can. J. Clin. Pharmacol., 2009, 16(1), e156-162.
154. Zhou, Q.; Yu, X.M.; Lin, H.B.; Wang, L.; Yun, Q.Z.; Hu, S.N.; Wang, D.M. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics. J., 2009, [Epub ahead of print].
155. Chen, L.; Qin, S.; Xie, J.; Tang, J.; Yang, L.; Shen, W.; Zhao, X.; Du, J.; He, G.; Feng, G.; He, L.; Xing, Q. Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics, 2008, 9(6), 691-702.
156. Okishiro, M.; Taguchi, T.; Jin Kim, S.; Shimazu, K.; Tamaki, Y.; Noguchi, S. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer, 2009, 115(5), 952-961.
157. Jinnai, T.; Horiuchi, H.; Makiyama, T.; Tazaki, J.; Tada, T.; Akao, M.; Ono, K.; Hoshino, K.; Naruse, Y.; Takahashi, K.; Watanabe, H.; Kita, T.; Kimura, T. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Circ. J., 2009, 73(8), 1498-1503.
158. Lee, S.S.; Lee, S.J.; Gwak, J.; Jung, H.J.; Thi-Le, H.; Song, I.S.; Kim, E.Y.; Shin, J.G. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther. Drug Monit., 2007, 29(4), 455-459.
159. Veiga, M.I.; Asimus, S.; Ferreira, P.E.; Martins, J.P.; Cavaco, I.; Ribeiro, V.; Hai, T.N.; Petzold, M.G.; Bjorkman, A.; Ashton, M.; Gil, J.P. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur. J. Clin. Pharmacol., 2009, 65(4), 355-363.
160. Tassaneeyakul, W.; Mahatthanatrakul, W.; Niwatananun, K.; Na-Bangchang, K.; Tawalee, A.; Krikreangsak, N.; and Cykleng, U. CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. Drug Metab. Pharmacokinet., 2006, 21(4), 286-290.
161. Pang, Y.S.; Wong, L.P.; Lee, T.C.; Mustafa, A.M.; Mohamed, Z.; Lang, C.C. Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. Br. J. Clin. Pharmacol., 2004, 58(3), 332-335. (Pubitemid 39209068)
162. Persson, I.; Aklillu, E.; Rodrigues, F.; Bertilsson, L.; Ingelman- Sundberg, M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics, 1996, 6(6), 521-526. (Pubitemid 27032304)
163. Herrlin, K.; Massele, A.Y.; Jande, M.; Alm, C.; Tybring, G.; Abdi, Y.A.; Wennerholm, A.; Johansson, I.; Dahl, M.L.; Bertilsson, L.; Gustafsson, L.L. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype. Clin. Pharmacol. Ther., 1998, 64(4), 391-401.
164. Masimirembwa, C.; Bertilsson, L.; Johansson, I.; Hasler, J.A.; Ingelman-Sundberg, M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin. Pharmacol. Ther., 1995, 57(6), 656-661.
165. Zychma, M.J.; Gumprecht, J.; Strojek, K.; Grzeszczak, W.; Moczulski, D.; Trautsolt, W.; Karasek, D. Sulfonylurea receptor gene 16-3 polymorphism - association with sulfonylurea or insulin treatment in type 2 diabetic subjects. Med. Sci. Monit., 2002, 8(7), CR512-515. (Pubitemid 34826773)
166. Elbein, S.C.; Sun, J.; Scroggin, E.; Teng, K.; Hasstedt, S.J. Role of common sequence variants in insulin secretion in familial type 2 diabetic kindreds: the sulfonylurea receptor, glucokinase, and hepatocyte nuclear factor 1alpha genes. Diabet. Care, 2001, 24(3), 472-478.